← Leaderboards
Anthony D Harris
University Of Maryland Baltimore
$19,569,894
Attributed
$21,363,973
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
CDC$11,002,582 · 4
NIH$6,839,637 · 4
AHRQ$3,521,754 · 3
VA$0 · 1
By mechanism
R01$7,599,600 · 5
U54$7,225,171 · 2
U01$2,930,694 · 1
K24$1,780,590 · 1
R18$1,166,418 · 1
K23$661,500 · 1
Top collaborators
- Eli N Perencevich4 shared
- Jesse Thomas Jacob2 shared
- Surbhi Leekha2 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Stephen J Meltzer$26,520,343
- Harry L. Mobley$24,735,775
- Barbara M Resnick$9,506,282
- Adam C Puche$4,246,001
- Marie Boltz$3,995,921
Others in their field
Top investigators on “Epidemiology”
- David Heimbrook · Leidos Biomedical Research, Inc.$390,770,069
- George R Seage · Abt Associates, Inc.$299,251,523
- Jeffrey P Krischer · University Of South Florida$264,076,260
- Barbara Driver · Westat, Inc.$221,167,491
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$206,739,528
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
EpidemiologyFundingPublishingPathogenInfection ControlHospitalsResearch PersonnelInfectionBacteriaCenters For Disease Control And Prevention (U.S.)Nosocomial InfectionsCommunicable DiseasesMorbidity - Disease RateComorbidityTransmission ProcessAntibiotic ResistanceRisk FactorsGrantPrincipal InvestigatorCareerMedicalPreventHealthcareMethodology
Grant awards (57)
Targeted Contact Precaution Use to Prevent MRSA Transmission$0
I01 · FY2025 · VA · contact PI
RFA-CK20-004: Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events$600,000
U54 · FY2024 · CK · contact PI
RFA-CK20-004: Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events$244,444
U54 · FY2024 · CK · contact PI
Targeted Contact Precaution Use to Prevent MRSA Transmission$0
I01 · FY2024 · VA · contact PI
Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events$1,424,035
U54 · FY2023 · CK · contact PI
Targeted Contact Precaution Use to Prevent MRSA Transmission$0
I01 · FY2023 · VA · contact PI
Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events$1,406,776
U54 · FY2022 · CK · contact PI
Targeted Contact Precaution Use to Prevent MRSA Transmission$0
I01 · FY2022 · VA · contact PI
Targeted Contact Precaution Use to Prevent MRSA Transmission$0
I01 · FY2021 · VA · contact PI
Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events$824,036
U54 · FY2020 · CK · contact PI
Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance andOther Adverse Events$544,792
U54 · FY2020 · CK · contact PI
Use of electronic data to improve risk adjustment for antibiotic utilization metrics$304,190
R01 · FY2020 · HS · contact PI
Epicenters for the Prevention of Healthcare-Associated Infections (HAIs); Cycle II Multicenter Program Studies$900,000
U01 · FY2019 · CK · contact PI
Epicenters for the Prevention of Healthcare-Associated Infections (HAIs); Cycle II Multicenter Program Studies$715,764
U01 · FY2019 · CK · contact PI
Epicenters for the Prevention of Healthcare-Associated Infections (HAIs); Cycle II Multicenter Program Studies$657,465
U01 · FY2019 · CK · contact PI
Epidemiology of CRE and MRSA transmission: patient and organism factors$640,614
R01 · FY2019 · AI · contact PI
Use of electronic data to improve risk adjustment for antibiotic utilization metrics$310,106
R01 · FY2019 · HS · contact PI
Epidemiology of CRE and MRSA transmission: patient and organism factors$52,994
R01 · FY2019 · AI · contact PI
Epicenters for the Prevention of Healthcare-Associated Infections (HAIs); Cycle II Multicenter Program Studies$657,465
U01 · FY2018 · CK · contact PI
Epidemiology of CRE and MRSA transmission: patient and organism factors$580,352
R01 · FY2018 · AI · contact PI
Use of electronic data to improve risk adjustment for antibiotic utilization metrics$391,951
R01 · FY2018 · HS · contact PI
K24 Clinical research in Antimicrobial Resistance and Hospital Epidemiology$176,113
K24 · FY2018 · AI · contact PI
Epidemiology of CRE and MRSA transmission: patient and organism factors$580,352
R01 · FY2017 · AI · contact PI
Does Universal Glove and Gown use decrease carbapenem-resistant Gram-negative bacteria$208,454
R18 · FY2017 · HS · contact PI
K24 Clinical research in Antimicrobial Resistance and Hospital Epidemiology$176,113
K24 · FY2017 · AI · contact PI
Epidemiology of CRE and MRSA transmission: patient and organism factors$606,118
R01 · FY2016 · AI · contact PI
Does Universal Glove and Gown use decrease carbapenem-resistant Gram-negative bacteria$475,504
R18 · FY2016 · HS · contact PI
Use of electronic data to improve risk adjustment for hospital infection rates$254,401
R01 · FY2016 · HS · contact PI
K24 Clinical research in Antimicrobial Resistance and Hospital Epidemiology$176,113
K24 · FY2016 · AI · contact PI
Epicenters for the Prevention of Healthcare Associated Infections (HAI) - Cycle II$2,181,088
U54 · FY2015 · CK · contact PI
Does Universal Glove and Gown use decrease carbapenem-resistant Gram-negative bacteria$482,460
R18 · FY2015 · HS · contact PI
Use of electronic data to improve risk adjustment for hospital infection rates$258,799
R01 · FY2015 · HS · contact PI
K24 Clinical research in Antimicrobial Resistance and Hospital Epidemiology$176,113
K24 · FY2015 · AI · contact PI
Use of electronic data to improve risk adjustment for hospital infection rates$368,265
R01 · FY2014 · HS · contact PI
K24 Clinical research in Antimicrobial Resistance and Hospital Epidemiology$176,113
K24 · FY2014 · AI · contact PI
Use of electronic data to improve risk adjustment for hospital infection rates$467,624
R01 · FY2013 · HS · contact PI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology$180,005
K24 · FY2013 · AI · contact PI
Epidemiology of emerging pathogens among hospitalizeds patients$170,826
R01 · FY2013 · AI · contact PI
Epidemiology of emerging pathogens among hospitalizeds patients$181,306
R01 · FY2012 · AI · contact PI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology$180,005
K24 · FY2012 · AI · contact PI
Epidemiology of emerging pathogens among hospitalizeds patients$180,177
R01 · FY2011 · AI · contact PI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology$180,005
K24 · FY2011 · AI · contact PI
Epidemiology of emerging pathogens among hospitalizeds patients$180,891
R01 · FY2010 · AI · contact PI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology$180,005
K24 · FY2010 · AI · contact PI
K24 Clinical Research in Antimicrobial Resistance and Hospital Epidemiology$180,005
K24 · FY2009 · AI · contact PI
New Nosocomial Interventions to Decrease Antimicrobial Resistance Transmission$297,748
R01 · FY2008 · CI · contact PI
Epidemiology of imipenem-resistant P.aeruginosa$138,129
R01 · FY2008 · AI · contact PI
Epidemiology of imipenem-resistant P.aeruginosa$352,012
R01 · FY2007 · AI · contact PI
New Nosocomial Interventions to Decrease Antimicrobial Resistance Transmission$294,937
R01 · FY2007 · CI · contact PI
Epidemiology of imipenem-resistant P.aeruginosa$362,526
R01 · FY2006 · AI · contact PI
New Nosocomial Interventions to Decrease Antimicrobial Resistance Transmission$254,032
R01 · FY2006 · CI · contact PI
Epidemiology of imipenem-resistant P.aeruginosa$371,250
R01 · FY2005 · AI
Study design importance in analyzing emerging pathogens$132,300
K23 · FY2005 · AI
Study design importance in analyzing emerging pathogens$132,300
K23 · FY2004 · AI
Study design importance in analyzing emerging pathogens$132,300
K23 · FY2003 · AI
Study design importance in analyzing emerging pathogens$132,300
K23 · FY2002 · AI
Study design importance in analyzing emerging pathogens$132,300
K23 · FY2001 · AI